|Application ||WB, E|
|Calculated MW||38954 Da|
|Other Names||Interferon-inducible protein AIM2, Absent in melanoma 2, AIM2|
|Target/Specificity||This AIM2 Monoclonal antibody is generated from mouses immunized with a KLH conjugated synthetic peptide selected from the 10-40 region of human AIM2.|
|Format||Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Euglobin precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||AIM2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Involved in innate immune response by recognizing cytosolic double-stranded DNA and inducing caspase-1-activating inflammasome formation in macrophages. Upon binding to DNA is thought to undergo oligomerization and to associate with PYCARD initiating the recruitment of caspase-1 precusrsor and processing of interleukin-1 beta and interleukin-18. Detects cytosolic dsDNA of viral and bacterial origin in a non-sequence-specific manner. Can also trigger PYCARD-dependent, caspase-1-independent cell death that involves caspase-8 (By similarity). Tumor suppressor which may act by repressing NF-kappa-B transcriptional activity.|
|Cellular Location||Nucleus. Cytoplasm. Note=Activated inflammasomes can aggregate in the cytosol as speck-like particles|
|Tissue Location||Expressed in spleen, small intestine, peripheral blood leukocytes, and testis|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Tumor suppressor which may act by repressing NF-kappa-B transcriptional activity.
DeYoung K.L., et al. Oncogene 15:453-457(1997).
Ota T., et al. Nat. Genet. 36:40-45(2004).
Gregory S.G., et al. Nature 441:315-321(2006).
Cresswell K.S., et al. Biochem. Biophys. Res. Commun. 326:417-424(2005).
Chen I.-F., et al. Mol. Cancer Ther. 5:1-7(2006).
If you have any additional inquiries please email technical services at email@example.com.